CRE-DR-H

CRE-DR-H is a humanized monoclonal antibody developed as a potential therapeutic for IgE-mediated allergic diseases and IgE-producing malignancies. It is derived from the mouse monoclonal antibody CRE-DR and specifically targets the elbow region of the CH3 domain of immunoglobulin E (IgE). The antibody is designed to selectively bind to membrane-bound IgE (mIgE) on the surface of B cells rather than circulating IgE or IgE already bound to high-affinity receptors on mast cells and basophils. By targeting mIgE, CRE-DR-H suppresses the proliferation of IgE-producing B cells and inhibits the secretion of IgE. Preclinical studies using the U266B1 human myeloma cell line have demonstrated its ability to significantly reduce cell viability and IgE production.

Other names

humanized CRE-DR